 - 51 patients with NRG1 cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date- Encouraging early clinical activity observed, with confirmed partial responses in 4 of 10 patients with pancreatic cancer 40 and in 9 of 33 patients across all NRG1 tumor types 27- Zenocutuzumab observed to be well tolerated with most adverse events being mild or moderate Grade 1 or 2- Oral presentation of an updated interim analysis of 45 evaluable patients to be presented at ASCO on June 4, 11 AM-2 PM ET- Company to host investor call to discuss clinical results and provide a program update on Sunday, June 6 at 6:00 PM ET 